Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1557-1564

  Takeuchi, Ario ^a   Shiota, Masaki ^a   Tatsugami, Katsunori ^a   Yokomizo, Akira ^a   Eto, Masatoshi ^b   Inokuchi, Junichi ^a   Kuroiwa, Kentaro ^a   Kiyoshima, Keijiro ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cytotoxic effect; S 1; Sorafenib; TS suppression

Indexed keywords

FLUOROURACIL; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MESSENGER RNA; SORAFENIB; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG SYNERGISM; E2F1 TRANSCRIPTION FACTOR; FEMALE; FLUOROURACIL; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; OXONIC ACID; PYRIDINES; RNA, MESSENGER; TEGAFUR; THYMIDYLATE SYNTHASE;

EID: 82455209085     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1660-6     Document Type: Article

References (41)

1. Mancuso A, Sternberg CN (2005) New treatments for metastatic kidney cancer. Can J Urol 12(Suppl 1):66-70 (discussion 105)
2. WG Kaelin Jr 2004 The von Hippel-Lindau tumor suppressor gene and kidney cancer Clin Cancer Res 10 6290S 6295S 15448019 10.1158/1078-0432.CCR-sup-040025 1:CAS:528:DC%2BD2cXnvVOjsb4%3D (Pubitemid 39287480)
3. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
4. YS Chang J Adnane PA Trail J Levy A Henderson D Xue E Bortolon M Ichetovkin C Chen A McNabola D Wilkie CA Carter IC Taylor M Lynch S Wilhelm 2007 Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models Cancer Chemother Pharmacol 59 561 574 17160391 10.1007/s00280-006-0393-4 1:CAS:528:DC%2BD2sXhvVeiuro%3D (Pubitemid 46295136)
5. Takeuchi A, Eto M, Tatsugami K, Yamada H, Oki T, Kiyoshima K, Yoshikai Y, Naito S (2010) Mechanism of synergistic antitumor effect of sorafenib and interferon-alpha on treatment of renal cell carcinoma. J Urol 184:2549-2556
6. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura M Fukushima 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557 8862723 10.1097/00001813-199607000-00010 1:CAS:528:DyaK28Xltleru78%3D (Pubitemid 26276346)
7. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004 4009 7689420 1:CAS:528:DyaK3sXmtFKqsrk%3D (Pubitemid 23267702)
8. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197 10765119 10.1159/000012099 1:CAS:528:DC%2BD3cXjvVeitr4%3D (Pubitemid 30189900)
9. K Shirao A Ohtsu H Takada Y Mitachi K Hirakawa N Horikoshi T Okamura K Hirata S Saitoh H Isomoto A Satoh 2004 Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma Cancer 100 2355 2361 15160338 10.1002/cncr.20277 1:CAS:528:DC%2BD2cXltFajsr4%3D (Pubitemid 38657882)
10. M Kawahara K Furuse Y Segawa K Yoshimori K Matsui S Kudoh K Hasegawa H Niitani 2001 Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 939 943 11592762 10.1054/bjoc.2001. 2031 1:CAS:528:DC%2BD3MXot1SktLg%3D (Pubitemid 33015993)
11. Y Inuyama A Kida M Tsukuda N Kohno B Satake 2001 Late phase II study of S-1 in patients with advanced head and neck cancer Gan To Kagaku Ryoho 28 1381 1390 11681245 1:STN:280:DC%2BD3Mrntl2isg%3D%3D
12. T Okusaka A Funakoshi J Furuse N Boku K Yamao S Ohkawa H Saito 2008 A late phase II study of S-1 for metastatic pancreatic cancer Cancer Chemother Pharmacol 61 615 621 17520253 10.1007/s00280-007-0514-8 1:CAS:528: DC%2BD1cXjsFWktw%3D%3D
13. J Furuse T Okusaka N Boku S Ohkawa A Sawaki T Masumoto A Funakoshi 2008 S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study Cancer Chemother Pharmacol 62 849 855 18214482 10.1007/s00280-007-0673-7 1:CAS:528:DC%2BD1cXht1CjtLvP
14. Naito S, Tsukamoto T, Usami M, Fujimoto H, Akaza H (2010) An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Cancer Chemother Pharmacol 66:1065-1070
15. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
16. Shiota M, Yokomizo A, Kashiwagi E, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N, Naito S (2010) Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Sci 101:1177-1185
17. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T, Naito S (2010) Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29:237-250
18. Shiota M, Eto M, Yokomizo A, Tada Y, Takeuchi A, Masubuchi D, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N, Naito S (2010) Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. Int J Oncol 36:1521-1531
19. T Okabe I Okamoto S Tsukioka J Uchida E Hatashita Y Yamada T Yoshida K Nishio M Fukuoka PA Janne K Nakagawa 2009 Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification Clin Cancer Res 15 907 913 19188161 10.1158/1078-0432.CCR-08-2251 1:CAS:528:DC%2BD1MXht1Onsbo%3D
20. T Okabe I Okamoto S Tsukioka J Uchida T Iwasa T Yoshida E Hatashita Y Yamada T Satoh K Tamura M Fukuoka K Nakagawa 2008 Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase Mol Cancer Ther 7 599 606 18347146 10.1158/1535-7163.MCT- 07-0567 1:CAS:528:DC%2BD1cXjtlWgsr4%3D (Pubitemid 351492458)
21. D Salonga KD Danenberg M Johnson R Metzger S Groshen DD Tsao-Wei HJ Lenz CG Leichman L Leichman RB Diasio PV Danenberg 2000 Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res 6 1322 1327 10778957 1:CAS:528:DC%2BD3cXjtVOqt74%3D (Pubitemid 30226214)
22. W Ichikawa H Uetake Y Shirota H Yamada N Nishi Z Nihei K Sugihara R Hirayama 2003 Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer Clin Cancer Res 9 786 791 12576451 1:CAS:528:DC%2BD3sXhtVKksbo%3D (Pubitemid 36182616)
23. J DeGregori T Kowalik JR Nevins 1995 Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes Mol Cell Biol 15 4215 4224 7623816 1:CAS:528:DyaK2MXntVGit7o%3D
24. Tanizaki J, Okamoto I, Takezawa K, Tsukioka S, Uchida J, Kiniwa M, Fukuoka M, Nakagawa K (2010) Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 9:1198-1207
25. WL Washtien 1984 Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil Mol Pharmacol 25 171 177 6708932 1:CAS:528: DyaL2cXps1aqsQ%3D%3D (Pubitemid 14223268)
26. CP Spears BG Gustavsson M Berne R Frosing L Bernstein AA Hayes 1988 Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil Cancer Res 48 5894 5900 3167844 1:STN:280:DyaL1M%2Fgt1Omsw%3D%3D
27. E Chu S Zinn D Boarman CJ Allegra 1990 Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line Cancer Res 50 5834 5840 1697502 1:CAS:528:DyaK3cXmtVCmtr4%3D (Pubitemid 20331386)
28. S Copur K Aiba JC Drake CJ Allegra E Chu 1995 Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil Biochem Pharmacol 49 1419 1426 7763285 10.1016/0006-2952(95)00067-A 1:CAS:528:DyaK2MXlvFSiur8%3D
29. E Chu DM Koeller PG Johnston S Zinn CJ Allegra 1993 Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma Mol Pharmacol 43 527 533 8474431 1:CAS:528:DyaK3sXkt1Kmsrg%3D (Pubitemid 23112729)
30. E Chu DM Voeller KL Jones T Takechi GF Maley F Maley S Segal CJ Allegra 1994 Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells Mol Cell Biol 14 207 213 8264588 1:CAS:528: DyaK2cXhtlSqsbc%3D
31. A Yoshioka S Tanaka O Hiraoka Y Koyama Y Hirota D Ayusawa T Seno C Garrett Y Wataya 1987 Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death J Biol Chem 262 8235 8241 2954951 1:CAS:528:DyaL2sXktlaktb4%3D
32. D Ayusawa K Shimizu H Koyama K Takeishi T Seno 1983 Accumulation of DNA strand breaks during thymineless death in thymidylate synthase-negative mutants of mouse FM3A cells J Biol Chem 258 12448 12454 6630193 1:CAS:528: DyaL3sXlvFalt7Y%3D
33. WC Lin FT Lin JR Nevins 2001 Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation Genes Dev 15 1833 1844 11459832 1:CAS:528:DC%2BD3MXlsFanu7g%3D (Pubitemid 32905640)
34. R Drago-Ferrante A Santulli R Di Fiore M Giuliano G Calvaruso G Tesoriere R Vento 2008 Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1 Int J Oncol 33 677 687 18813780 1:CAS:528:DC%2BD1cXht1KhtbnL
35. SP Chellappan S Hiebert M Mudryj JM Horowitz JR Nevins 1991 The E2F transcription factor is a cellular target for the RB protein Cell 65 1053 1061 1828392 10.1016/0092-8674(91)90557-F 1:CAS:528:DyaK3MXks12nsrg%3D (Pubitemid 121001693)
36. JR Nevins 1998 Toward an understanding of the functional complexity of the E2F and retinoblastoma families Cell Growth Differ 9 585 593 9716176 1:CAS:528:DyaK1cXlsVWqtLs%3D (Pubitemid 28367248)
37. TC Hallstrom JR Nevins 2003 Specificity in the activation and control of transcription factor E2F-dependent apoptosis Proc Natl Acad Sci USA 100 10848 10853 12954980 10.1073/pnas.1831408100 1:CAS:528:DC%2BD3sXnslynt7Y%3D (Pubitemid 37140116)
38. K Liu JC Paik B Wang FT Lin WC Lin 2006 Regulation of TopBP1 oligomerization by Akt/PKB for cell survival EMBO J 25 4795 4807 17006541 10.1038/sj.emboj.7601355 1:CAS:528:DC%2BD28XhtVyktb7O (Pubitemid 44607025)
39. T Ahmad T Eisen 2004 Kinase inhibition with BAY 43-9006 in renal cell carcinoma Clin Cancer Res 10 6388S 6392S 15448036 10.1158/1078-0432.CCR-040028 1:CAS:528:DC%2BD2cXnvVOjtrw%3D (Pubitemid 39302607)
40. Pillai S, Kovacs M, Chellappan S (2010) Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation. Cancer Res 70:4931-4940
41. Miller RE, Larkin JM (2009) Combination systemic therapy for advanced renal cell carcinoma. Oncologist 14(12):1218-1224